Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Interventional Radiology In Brief

This article was originally published in The Gray Sheet

Executive Summary

Embolization/RF ablation for liver cancer: Combining minimally-invasive embolization and ablation is as effective as surgery for treating single tumors up to 7 cm in diameter, according to a study abstract presented by Anne Covey, MD, Memorial Sloan Kettering Cancer Center, at the Society of Interventional Radiology annual scientific meeting March 25-30 in Phoenix. Although patients with more advanced liver cancer were treated with the combined treatment, survival rates at one, two, four and five years were 97%, 83%, 77% and 56% compared with 81%, 70%, 70% and 57% for the surgery group. Boston Scientific (Contour SE) and BioSphere Medical (Embosphere Microspheres) are among the firms offering embolization devices, and Boston Scientific (RF 3000), Tyco (Cool-tip) and Rita Medical (Starburst) market RF ablation systems...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts